Nutra Pharma has announced that it has successfully completed submission of final packaging and labeling to the Food and Drug Administration (FDA) to begin selling its over-the-counter (OTC) pain reliever, Cobroxin.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.
“Successfully submitting the final packaging and labeling to the FDA was the final step required for Nutra Pharma to begin selling and marketing Cobroxin,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As we move forward with this launch, we plan to have Cobroxin available for sale at select online and brick-and-mortar retailers as early as October,” he added.
Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating repetitive stress, arthritis, and joint pain.
Additional benefits to Cobroxin include:
- All Natural
- More Potent than Morphine
- Long Lasting
“Based on the positive feedback we have already received from pharmacists and consumers about Cobroxin, we are now even more confident that this drug will soon become the preferred OTC pain reliever for those with moderate to severe chronic pain,” commented Dr. Paul Reid, CEO of ReceptoPharm. “In addition to our focus on Cobroxin, we are continuing to finalize additional product formulations to bring to market, including a prescription-only analgesic and a pain reliever for the veterinary market,” he concluded.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Submitting final Cobroxin packaging and labeling to the FDA should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.